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Abstract 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
duloxetine is effective in reducing pain for patients with diabetic neuropathy. 
STUDY DESIGN: Systematic review of three English language Randomized Controlled 
Trials, published between 2010-2015. 
DATA SOURCES: Three randomized controlled trials published in peer-reviewed 
journals comparing the effects of Duloxetine on diabetic neuropathy pain found using the 
Embase database.  
OUTCOME MEASURES: The outcomes were measured by assessing diabetic neuropathy pain 
reduction, using the Brief Pain Inventory (BPI) average pain item, BPI- severity scale, BPI- 
interference. Also, individual health outcome was measured by using Patient Global Impression 
of Improvement (PGI)- Improvement scale, Sheehan Disability Scale (SDS), and Clinical Global 
Impressions of Severity (CGI-S). 
RESULTS: Three studies in the review showed a significant pain reduction for patients with the 
diabetic neuropathic pain taking a duloxetine vs. a placebo. However, Gao and co-authors 
showed no statistically different mean change in BPI average pain reduction from baseline to 
endpoint between the treatment groups in week 8 (p= 0.125) and 12 (p=0.107).  The other two 
studies showed the statistical significance of primary efficacy results as “p” <0.0001 and “p”= 
0.030. All three studies showed significant health outcome measured in BPI-interference and 
NNT. 
CONCLUSIONS: There is a significant benefit of using duloxetine for the diabetic neuropathic 
pain vs. placebo. The most common adverse effect of Duloxetine is nausea, which may 
discourage the usage and its therapeutic benefit in pain reduction for diabetic neuropathic pain 
(DNP). Further investigation in the long-term study will reinforce the efficacy and safety of 
duloxetine as the diabetic neuropathic pain treatment.  
KEYWORDS: Diabetic neuropathy, Duloxetine
Namgoong, Duloxetine efficacy for diabetic neuropathy 1 
 
INTRODUCTION 
Diabetic neuropathy is the pain characterized by aching, burning, tingling or stabbing 
sensation that is often increased at night and affects sleep, but also interferes with daily life, 
leading to deterioration of the quality of life and a depressive state in severe cases. Diabetes 
mellitus type I and II both have many severe complications due to dysfunctional glucose 
metabolism, resulting damage to organs, and vessels. Thus, peripheral nerves with a 
compromised blood supply also suffer, which may render impaired function of nerves that cause 
mild to debilitating pain sensations for diabetic patients.1 However, the pathophysiology of the 
diabetic neuropathic pain is not entirely understood.2 
Duloxetine has proven efficacy, relative safety profile, and has been approved for 
managing the diabetic neuropathic pain. Duloxetine is considered a serotonin and norepinephrine 
reuptake inhibitor (SNRI). Both serotonin and norepinephrine are neurotransmitters that are an 
essential part of endogenous pain inhibitory mechanisms in the central nervous system.2 Thus, by 
inhibiting the clearance of those neurotransmitters in the CNS, the pain-transmitting pathway is 
kept at bay longer. For this reason, chronic pain can be managed with duloxetine. Duloxetine is 
also used to treat major depressive disorder, generalized anxiety disorder, fibromyalgia, and 
chronic muscle or joint pain. Diabetic neuropathic pain dosage starts at 30 mg daily and may 
increase to 60 mg daily; maximum dose of 120 mg may not be more efficacious than 60 mg.2 
A common complication of type 1 and type 2 diabetes is painful neuropathy in the arms 
and legs. About a quarter of type 2 diabetes patients exhibit nerve damage at the time of 
diagnosis. Diabetic neuropathy has a lifetime prevalence of approximately 50%.1 In the US, 
diabetes health-care cost $245 billion in 2012. Nearly 27% of costs of diabetes is due to diabetes 
neuropathy.1 Diabetic neuropathic patients experience a two-fold increase in health-care 
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expenses at $12,492, and those with severe painful peripheral neuropathy experience a four-fold 
increase at $30,755.1 
Currently, we understand the diabetic neuropathy of its epidemiology, etiology, signs, 
symptoms, diagnostic tests, treatment, and management options. However, the pathophysiology 
and the interaction between diabetes neuropathy and metabolic risk factors remain unknown. 
Diabetic neuropathic pain is managed with pain control using antidepressants, such as TCAs and 
SNRIs. Anticonvulsants, including pregabalin and gabapentin, are also used as treatment option.2 
Diabetic neuropathy is commonly insidious and can lead to foot ulcers, muscle and joint disease 
due to progressive sensory loss.2 Duloxetine works against the pain-transmitting pathway to 
prevent sensory loss and complications, such as foot ulcers. The benefit of duloxetine was 
established in three 12-week, randomized, blinded, and controlled trials that showed a rapid 
onset of action and sustained benefit with efficacy in relieving diabetic neuropathic pain at 
night.2 
 
OBJECTIVE 
“The objective of this selective EBM review is to determine whether or not Duloxetine is 
effective in reducing pain with diabetic neuropathy.” 
 
METHODS 
The keywords used on Embase for this systematic review research include “diabetic 
neuropathy” and “duloxetine”. Three double-blinded, randomized controlled trial studies were 
found on Embase that target the patient population with diabetic neuropathy, using duloxetine 
therapy as intervention vs. placebo therapy to examine the efficacy of duloxetine in reducing 
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neuropathic pain. In addition, these three randomized controlled trial studies measured the 
quality of life as in a relationship with others, sleeping, walking ability, mood, and enjoyment of 
life. Therefore, they are Patient-Oriented Evidence that Matters (POEM) based studies with the 
intention to treat. These three studies, Gao 2010, Yasuda 2011, and Guo 2015, were published in 
peer-reviewed journals in the English language, between 2010 and present. 
Inclusion criteria used for this review were RCTs published since 2000, the subject’s age 
between 20 and 80, diabetic peripheral neuropathic daily pain, and type I, II diabetes. Exclusion 
criteria used for this review were the use combination therapy, unstable glycemic control, and the 
presence of severe comorbid conditions. 
This systematic review presents various measurements used in three RCT studies to 
demonstrate the clinical significance of the duloxetine intervention vs. placebo, including LS 
mean changes, “p”-values, number needed to treat (NNT), number needed to harm (NNH), 
relative benefit increase (RBI), absolute benefit increase (ABI), and confidence interval (CI). 
 
Table 1. the demographics and characteristics of the included studies 
Study Type # of 
pts 
Age Inclusion criteria Exclusion criteria W/D Interventions 
Gao, 
2010 (1) 
RCT 215 ≥ 18 
yrs 
- Patients with diabetic 
peripheral neuropathy had 
a rating of ≥4 on the Brief 
Pain Inventory 24-hour 
average pain item 
- Men and women 
- daily pain for ≥6 months 
before entry into the study 
- unstable glycemic control 
(Hgb A1c >12%) 
-any medical or other 
condition mania, bipolar 
disorder, psychosis 
-at risk for suicide as judged 
by the investigator 
- taking any monoamine 
oxidase inhibitors within 14 
days before visit 2 
- history of hepatic 
dysfunction or other severe 
medical conditions 
36 60 or 120 mg 
of duloxetine 
vs. matching 
placebo. 
Namgoong, Duloxetine efficacy for diabetic neuropathy 4 
 
Yasuda, 
2011 (2) 
RCT 339 20 - 
<80 
yrs 
- men and women 
-have sustained pain for ≥ 
6 months as a result of 
distal symmetric 
polyneuropathy caused by 
type 1 or type 2 diabetes 
mellitus 
- glycated hemoglobin 
(HbA1c) ≤ 9.4% at 
screening, fluctuation of 
HbA1c ≤ 1.0% at 42–70 
days before screening 
-the 24-h average pain 
score rated by the 11-point 
Rating Scale ≥ 4 
- patients with psychiatric 
diseases, i.e., mania, bipolar 
disorder, depression, anxiety 
disorders, eating disorders, or 
patients with a history of any 
pharmacotherapy during the 
past year. 
- Complication that might 
affect the assessment of 
DNP, i.e., neurological 
disorders unrelated to 
diabetic neuropathy, a skin 
condition in the area could 
alter sensation and other 
painful conditions. 
1 duloxetine 40 
or 60 mg/day 
once daily vs. 
placebo 
against DNP. 
Guo & 
Gao, 
2015 (3) 
RCT 405 ≥ 18 
yrs 
- DPNP had a rating of ≥ 4 
on the Brief Pain 
Inventory-Modified Short 
Form-Severity weekly 
average pain item. 
-Presented with bilateral 
DPNP began in the feet 
with relatively 
symmetrical onset. 
-The daily pain had to be 
present for at least 6 
months. 
-unstable glycemic control 
(hemoglobin A1c > 12%) 
-mental illnesses, the risk for 
suicide 
-serious or unstable 
cardiovascular, hepatic, 
renal, respiratory, or 
hematological illness 
-symptomatic peripheral 
vascular disease 
-Presence of other serious 
medical conditions. 
56 Duloxetine 60 
mg/day vs. 
placebo against 
DNP. 
 
OUTCOME MEASURES 
Three studies in this systematic review measured the outcome of pain reduction as a 
result of duloxetine intervention vs. placebo with various scales. The first study by Gao 2010 
measured the Brief Pain Inventory (BPI) average pain item as the primary efficacy, measuring 
24-h average pain score on an 11-point Likert scale, 0 being “no pain” and 10 being “worst 
possible” by patients. The secondary efficacy outcome measures the BPI-severity and BPI-
interference that assess the pain severity and interference with function, 0 being “no 
interference” to 10 being “complete interference.” Another secondary efficacy measure was the 
BPI average pain of 30% and 50% reduction from baseline to endpoint.  In addition, the Clinical 
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Global Impressions of Severity (CGI-S), the Patient Global Impression of Improvement (PGI-I), 
and the Athens Insomnia Scale (AIS) were also measured.2 
The second study by Yasuda 2011 measured the weekly mean 24-h average pain severity 
score on the 11-point scale as a primary efficacy. A secondary efficacy was measured by the pain 
severity for 24-h worst pain and night pain on an 11-point scale. Also, Patient’s Global 
Impression of Improvement (PGI-I) Scale, which is a 7-point scale, 1 being “very much 
improved” and 7 being “very much worse” was recorded at 2, 4, 8, and 12 weeks. In addition, 
the severity and interference portions of Brief Pain Inventory (BPI) recorded at randomization 
and weeks 2, 4, 8 and 12.3 
The third study by Guo 2015 collected data of the weekly mean of daily pain ratings 
including average, worst, and night pain on an 11-point Likert scale as a primary efficacy 
measure. The BPI-S and the PGI-I were secondary efficacy measures. Additionally, the BPI-I, 
which ranges from 0 being “does not interfere” with 10 being “completely interferes” and the 
Sheehan Disability Scale, SDS, which range from 0 being “not at all” to 10 being “extremely” 
were assessed for the health outcome.4 
RESULTS 
The Gao 2010 study showed statistically insignificant differences in the LS mean changes 
of BPI 24-h average pain as –2.31±0.18 in the placebo group and –2.69±0.19 in duloxetine 
treatment groups, “p” =0.124. However, there was a significant difference in placebo and 
duloxetine group in secondary efficacy measures, including BPI-S and BPI-I item. During the 
12-week period, the BPI-S item “pain right now” was significantly decreased at “p” =0.012 and 
the BPI-I item “walking ability” showed improvement at “p” =0.016. In addition, the other 
secondary efficacy measures, CGI-S at P=0.036 and PGI-I at “p” =0.028, were signaled 
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remarkable improvement in duloxetine group. Table 2 and 2-1 shown below explains the above 
results.2 
In regards to safety, the rate of adverse events was not statistically significant between 
the two groups. However, treatment-emergent adverse events (TEAEs) revealed following 
results: nausea at “p” = 0.0001, somnolence at “p” = 0.015, anorexia at “p” =0.010, and dysuria 
at “p” = 0.009. Duloxetine-treated patients had 16.7% of discontinuation rate as opposed to 
placebo group in 3.7% due to adverse effects.2 
 
Table 2. Brief Pain Inventory 24-hour average pain as assessed by LOCF 
Group\ measures Baseline to endpoint 
LS mean changes 
Statistical significance 
(“p” value) 
Placebo –2.31±0.18 “p”=0.124 
Duloxetine treatment –2.69±0.19 “p”=0.124 
 
Table 2-1. Secondary efficacy measures as assessed by LOCF 
Group\ measures BPI-severity 
: pain right 
now 
BPI-interference 
: walking ability 
PGI-I 
Patient Global 
Impression of 
Improvement 
CGI-S 
Clinical Global 
Impressions of 
Severity 
Placebo -1.99±0.25 -1.82±0.23 2.64±0.10 -0.99±0.11 
Duloxetine -2.72±0.26 -2.45±0.24 2.32±0.11 -1.24±0.11 
“p” value 0.012 0.016 0.028 0.036 
 
The 24-h average pain score demonstrated a significant improvement in the duloxetine 40 
and 60 mg groups vs. placebo group in the Yasuda 2011 study with a “p” value <0.0001. The 24-
h average pain score compared from baseline to endpoint has following mean changes: the 
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combined duloxetine at -2.47 ± 0.18, duloxetine 40 mg at -2.41 ± 0.21, duloxetine 60 mg at -2.53 
± 0.21, and placebo groups at -1.61 ± 0.18. As secondary efficacy measures, significant 
improvement in the health outcome was noted in BPI-I score in walking ability at “p”= 0.0228, 
relationship with other people at “p” = 0.0076, sleep at “p”= 0.0378, and enjoyment of life at 
“p”= 0.0089. Table 3 and 3-1 shown below explains the above results.3 
About 8.8% of study subjects left the study due to adverse effects, including somnolence 
at “p” =0.0007, nausea at “p” <0.0001, and dizziness at “p”= 0.0354. Higher incidence rate of 
adverse effects in duloxetine-treated group vs. placebo group was statistically significant at “p”= 
0.0153.3 
 
Table 3. Mean changes of the 24-h average pain over 12 week 
Group\ measures Baseline to endpoint 
LS mean changes 
Statistical significance 
(p value) 
Combined duloxetine -2.47 ± 0.18 Week 1,2,3 & 6 
= “p” <0.005 
 
Week 4,5,7,8,9,10 &11 
= “p” <0.0001 
40 mg duloxetine -2.41 ± 0.21 
60 mg duloxetine -2.53 ± 0.21 
Placebo -1.61 ± 0.18 
 
Table 3-1. Mean changes of BPI-Interference over 12 week 
 
Walking ability Relationship 
with other 
Sleep Enjoyment  
of life 
Combined duloxetine -2.31±0.23 -1.32±0.23 -2.15±0.24 -2.15±0.23 
Placebo -1.82±0.23 -0.77±0.23 -1.69±0.24 -1.59±0.23 
“p” value 0.0228 0.0076 0.0378 0.0089 
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Duloxetine-treated patients experienced significantly higher pain relief compared to that 
of placebo-treated patients in Guo 2015 study. As primary efficacy measure, 12th week LS mean 
change of 24-h average pain in duloxetine was measured at -2.40±0.14 and placebo at -
1.97±0.14. Its LS mean change difference with 95% CI was -0.43 with “p” = 0.030. The pain 
reduction of 50% in BPI-Severity average pain was collected as 46.0% in the duloxetine-treated 
group and 29.4% in the placebo group with “p” = 0.001 and NNT = 6.0. Table 4 and 4-1 shown 
below explains the above results.4 
Discontinue rate of the duloxetine-treated group was higher at 8.4 % than that of the 
placebo group at 4.0%. Statistical significance between the two groups in adverse events as 
following: nausea at “p” =0.010, somnolence at “p” <0.001, and asthenia at “p” =0.002.4 Table 
4-2 shown below explains the above results.4 
 
Table 4. LS mean changes of 24-h average pain 
Group\ measures Baseline to endpoint 
LS mean changes 
Statistical significance 
(“p” value) 
Placebo –1.97±0.14 “p”=0.030 
Duloxetine treatment –2.40±0.14 “p”=0.030 
 
 
Table 4-1. BPI-severity average pain 50% reduction “p” = 0.001 
CER 
Placebo-
treated 
EER 
Duloxetine-
treated 
Relative benefit 
increase (RBI) 
EER- CER 
CER 
Absolute 
benefit increase 
(ABI) 
EER - CER 
Number 
needed to treat 
(NNT) 
1/ABI 
0.294 0.46 0.56 0.166 6.02 
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Table 4-2. Treatment-emergent adverse events 
 
 Nausea Somnolence Asthenia 
“p” value 0.010 <0.001 0.002 
NNH 14.5 12.7 20.0 
 
DISCUSSION 
Duloxetine is one of the SNRI drugs that has been widely used for treating major 
depressive disorder and generalized anxiety disorder. It is also used for chronic pain symptoms, 
such as fibromyalgia, diabetic neuropathy, and chronic low back pain. This drug is used as ‘off-
label’ for osteoarthritis of the knee and stress urinary incontinence in women. The FDA has 
approved Cymbalta in 2004, which is the brand name for duloxetine. The generic version of 
Cymbalta in the delayed-release capsule was approved by the FDA in 2013. Duloxetine is 
covered by many commercial insurance plans and Medicare, which makes the drug more 
accessible. Coupons can also be found online, which decreases the price of duloxetine at local 
pharmacies even further.5 
            Duloxetine has the FDA black box warning of increased risk for suicidal thoughts and 
behavior, which is common in the antidepressant drug class. Duloxetine should not be used 
concurrently or within 2 weeks of discontinuation of monoamine oxidase inhibitors (MAOIs) for 
treating psychiatric disorders. Similarly, patients on linezolid or IV methylene blue should 
refrain from using duloxetine. More common adverse reactions to duloxetine include headaches, 
drowsiness, fatigue, nausea, abdominal pain, weight loss, and weakness. Less common adverse 
reactions to duloxetine include flushing, increased blood pressure, palpitations, insomnia, 
dizziness, agitation, diaphoresis, decreased libido, constipation, diarrhea, erectile dysfunction, 
and tremor.5 
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During the search for Randomized Controlled Trial studies for this review on PubMed 
and Embase, it was challenging to find studies on duloxetine monotherapy regime. Also, during 
the search, the RCT studies on treating diabetic neuropathy pain frequently presented different 
treatment modalities, including TCAs, anticonvulsants, and opioids. 
Each study in this systematic review—Gao 2010, Yasuda 2011, and Guo 2015—
presented the various limitations of their studies. In the study by Gao 2010, the outcome may be 
affected by the higher placebo response in Asian studies compared with western studies. The 
major depressive disorder patients included in this study may have yielded a high placebo 
response. Despite the fact that the other two studies were also conducted in Asia, less bias in 
their studies was suspected as they excluded the major depressive disorder patients from their 
studies. All three studies were conducted over 12 weeks, which lacks the long-term effect of the 
drug on study subjects. 
 
CONCLUSION 
Three randomized controlled trial studies in this systematic review investigated the 
efficacy of duloxetine therapy for treating diabetic neuropathy. The outcome measured in those 
studies showed a statistical significance in pain reduction as well as the improvement of the 
quality of life in diabetic neuropathy patients. Despite the potential adverse reactions of 
duloxetine therapy, diabetic neuropathy patients can be benefited in symptom reduction, 
preventing worsening pain, and its complications. 
In regards to the methodology of randomized controlled trials, one can dispute the 
validity of brief pain inventory score as it is based on patient’s subjective pain rating. To achieve 
reliable and reproducible outcomes of RCT studies, study subjects must be able to rate their pain 
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objectively without being biased by variable personal pain tolerance level. For that reason, future 
RCT studies may incorporate ways to ensure a universal pain rating method. Moreover, future 
RCT studies using duloxetine as monotherapy for treating diabetic neuropathy for different 
ethnic backgrounds and over an extended period will strengthen the conclusion of this systematic 
review. Lastly, future RCT studies showing the duloxetine efficacy in comparison of two groups 
with early and late onset symptomatic neuropathy patients would guide clinicians when to 
initiate duloxetine therapy for maximum benefit. 
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